Lytone Enterprise, Inc (1293) Fair Value & Analysis
Consumer Defensive · TW · Market cap 468M TWD
Fair value as of: Jun 24, 2026
Analysis
Lytone Enterprise, Inc (1293) currently trades at 27.85 TWD, while our model-based Fair Value estimate is 40.11 TWD — implying the stock looks roughly 44.0% undervalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Lytone Enterprise, Inc. engages in the research, design, and development of functional food products, and animal husbandry and agricultural biotechnology products in Taiwan. It offers post-harvest techniques; functional fertilizers; and livestock feed additives comprising immune stimulators, growth promoters, and health improvement products. The company also provides food ingredients, such as plant extracts, animal tissue extracts, and probiotics; and healthy foods, including metabolic syndrome improvements, skin and hair care, neuroprotection, gastrointestinal care, and allergy improvement products. It operates in China, Europe, the United States, Japan, Korea, Southeast Asia, New Zealand, Australia, and East Africa. Lytone Enterprise, Inc. was founded in 1994 and is headquartered in New Taipei City, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Lytone Enterprise, Inc (1293) undervalued?
What is the fair value of 1293?
What is the quality score of 1293?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.